Catalent Inc. (CTLT) News
Filter CTLT News Items
CTLT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CTLT News Highlights
- For CTLT, its 30 day story count is now at 26.
- Over the past 21 days, the trend for CTLT's stories per day has been choppy and unclear. It has oscillated between 1 and 10.
- The most mentioned tickers in articles about CTLT are ACOR, FCF and GENE.
Latest CTLT News From Around the Web
Below are the latest news stories about CATALENT INC that investors may wish to consider to help them evaluate CTLT as an investment opportunity.
Taro Pharmaceutical (TARO) Lags Q3 Earnings and Revenue EstimatesTaro (TARO) delivered earnings and revenue surprises of -78.16% and 14.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Reasons for the Decline of Catalent (CTLT) StockArtisan Partners, an investment management company, released its “Artisan Mid Cap Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, its Investor Class fund ARTMX returned -1.13%, Advisor Class fund APDMX posted a return of -1.12%, and Institutional Class fund APHMX returned -1.07%, compared to a […] |
Catalent, Inc. Announces Second Quarter Fiscal Year 2023 Earnings Conference WebcastCatalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply o |
Catalent (CTLT ) Presents At 41st Annual Healthcare Conference - Slideshow (NYSE:CTLT)The following slide deck was published by Catalent, Inc. |
Catalent Appoints Ricardo Zayas as North American Biologics Operations LeaderSOMERSET, N.J., January 17, 2023--Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader |
Catalent's (CTLT) New Deal to Utilize Its Zydis ODT TechnologyCatalent's (CTLT) latest development and license agreement is expected to accelerate the administration of therapeutic doses of active drugs. |
Johnson & Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 ShotJohnson & Johnson (NYSE: JNJ) has significantly scaled back its efforts of manufacturing its COVID-19 vaccine after facing a fall in demand. The FDA approved the single-dose shot in February 2021 as it carried fewer cold-chain storage requirements than other shots. J&J's initial supply was small. At least nine companies agreed to help manufacture J&J's shot. Wall Street Journal noted. Yet J&J's vaccine hasn't been as widely used as the Moderna Inc (NASDAQ: MRNA) or Pfizer Inc (NYSE: PFE) and Bio |
J&J Slashes Production of Its Unpopular Covid-19 ShotJohnson & Johnson in recent months terminated manufacturing agreements with companies that helped produce the shot during the pandemic. |
Is Catalent Inc. (NYSE: CTLT) Stock Set To Rise More?In the latest trading session,, 1.21 million Catalent Inc. (NYSE:CTLT) shares changed hands as the company’s beta touched 1.22. With the company’s most recent per share price at $48.28 changing hands around $0.1 or 0.20% at last look, the market valuation stands at $8.40B. CTLT’s current price is a discount, trading about -147.97% off its … Is Catalent Inc. (NYSE: CTLT) Stock Set To Rise More? Read More » |
Avantor® and Catalent Enter into Multi-Year Supply and Services AgreementAvantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, today announced that it has entered into a multi-year supply and services agreement with Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide. Under the terms of the agreement, Avantor will be the primary supplier of a broad range of laborator |